Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review-Reference-Cited by-同舟云学术

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review

Published:2024-01 Issue:1 Volume:40 Page:18-29
ISSN:0740-9303
Container-title:Ophthalmic Plastic & Reconstructive Surgery
language:en
Short-container-title:

Author:

Serbest Ceylanoglu Kubra¹²,Guneri Beser Buse¹,Singalavanija Tassapol¹³,Juntipwong Sarinee¹,Worden Francis Paul⁴,Demirci Hakan¹

Affiliation:

1. Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A.

2. Department of Ophthalmology, University of Health Sciences, Ulucanlar Eye Training and Research Hospital, Ankara, Turkiye

3. Department of Ophthalmology, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand

4. Division of Hematology-Oncology, Department of Internal Medicine, Roger Cancer Center, University of Michigan, Ann Arbor, Michigan, U.S.A.

Abstract

Purpose: To review the outcomes of targeted therapy and immunotherapy in advanced conjunctival tumors, including conjunctival squamous cell carcinoma, conjunctival melanoma, and conjunctival lymphoma. Methods: A Pubmed database systematic search was performed between January 1999 and December 2022. The literature search was limited to studies published in English. Results: This review included 142 patients with advanced malignant conjunctival tumors from 42 articles. In the conjunctival squamous cell carcinoma group, 2 cases of advanced conjunctival squamous cell carcinoma treated with epidermal growth factor receptor inhibitors showed significant tumor size improvement after 7.5 months of follow-up. Among 7 cases treated with systemic immunotherapy, 5 cases (72%) had complete response (CR), 1 case (14%) showed partial response (PR), and 1 case (14%) had stable disease (SD) after 16 months. In the conjunctival melanoma group, among 18 cases treated with combined v-raf murine sarcoma viral oncogene homolog B1/mitogen-activated extracellular signal-regulated kinase inhibitors, 6 (33%) had CR, 5 (28%) had PR, 2 (11%) had SD, and 5 (28%) had progressive disease after 24.8 months of follow-up. Of 44 conjunctival melanoma cases treated with immunotherapy, 12 (28%) had CR, 9 (20%) had PR, 7(16%) had SD, and 16 (36%) had progressive disease after 14.2 months. Systemic Rituximab treatment for conjunctival lymphoma cases resulted in CR in 21 patients (63%), PR in 11 patients (33%), and SD in 1 patient (3%) after 20.5 months of follow-up. Intralesional Rituximab injections in 38 conjunctival lymphoma cases showed CR in 28 patients (75%), PR in 7 patients (19%), SD in 1 patient (2%), and progressive disease in 2 patients (4%) after 20.4 months of follow-up. Conclusions: Despite limited clinical case reports and short-term follow-ups, targeted therapy and immunotherapy have shown promising results for advanced malignant conjunctival tumors.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine,Surgery

Reference75 articles.

1. Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--the 2017 J. Donald M. Gass Lecture.;Shields;Asia Pac J Ophthalmol (Phila),2017

2. Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP diet and health study.;Emmanuel;Ecancermedicalscience,2012

3. Surgical management of conjunctival tumors. the 1994 Lynn B. McMahan Lecture.;Shields;Arch Ophthalmol,1997

4. Ocular surface squamous neoplasia.;Lee;Surv Ophthalmol,1995

5. Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment.;Sakai;PLoS One,2020